Key Drivers
- Very high gross-margin
- Large cash cushion
- Elevated operating burn
AIAI Summary
Apellis is no longer just a clinical binary bet but a high‑leverage commercial turnaround: the valuation now hinges on management proving SYFOVRE can stabilize or EMPAVELI can scale into a multi‑hundred‑million revenue engine while SG&A growth is tamed, with its cash roughly offsetting debt giving time to execute. Monitor sequential SYFOVRE revenue trends, EMPAVELI start-form and payer traction, and quarterly SG&A deceleration as the specific triggers that will materially re‑rate (or de-rate) the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross-margin
- •Large cash cushion
- •Elevated operating burn
APLS combines very high gross margins and a large cash buffer that largely offsets debt, but heavy R&D/SG&A, quarterly losses and rich valuation pose material risks to returns.
Price Behavior
Key Price Behavior Insights:
- •Strong downtrend
- •Trading at low
- •Short-term oversold
Over the last month APLS plunged about 22.7% to the period low near $17.21, showing strong downward momentum but short-term oversold positioning with near support at $17.21–$18.8 and resistance between $20.7–$23.5.
~22.7% drop from ~$22.28 to $17.21 over last month
Sentiment & News
Key News Insights:
- •EPS beat
- •SYFOVRE decline
- •EMPAVELI surge
Apellis reported mixed Q4/2025 results with EPS beats but revenue and SYFOVRE declines offset by strong EMPAVELI growth, strategic pipeline and board moves, and new institutional buying.
The split product performance and fresh institutional accumulation likely keep the stock volatile near-term while strategic pipeline progress supports longer-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings